Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44)

archived

Purpose. This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) proposing research towards commercial development of emerging molecular and/or cellular analytical technologies intended for cancer detection and/or characterization. The goal of this FOA is to facilitate the translation of innovative, cancer-relevant technologies into commercial products and/or services. The emphasis is on molecular analysis technologies to improve cancer prevention, detection and diagnosis, surveillance, epidemiological research, and basic cancer research. These technologies may be intended for molecular and cellular analyses in vitro, in situ, and/or in vivo. There must be sound rationale pointing to the commercial potential of the technology to be developed. Mechanism of Support. This FOA will utilize the SBIR R43/R44 grant mechanisms for Phase I, Phase II, and Fast-Track applications. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of five to seven projects awarded under this announcement is $2 million for fiscal year 2011. Future year amounts will depend on annual appropriations.

High